High-CBD Cannabis Extracts Suppressed Gut Inflammation Through microRNA Pathways

In vitro study using human small intestinal epithelial cells (HSIEC) stimulated with TNF-alpha/IFN-gamma to model inflammation. Five high-CBD cannabis extracts tested for effects on COX-2, SOCS3, IL-6, IL-8, and cell growth. MicroRNA profiling identified miR-760 and miR-302c-3p as mediators. Individual prevalent components tested both alone and in combination.

Inflammatory bowel diseases are growing worldwide and current treatments have significant limitations. If CBD-based therapies can target gut inflammation through miRNA pathways, they could complement or offer alternatives to existing approaches. The miRNA mechanism is particularly interesting because it suggests a more fundamental regulation of inflammation rather than just suppressing surface-level symptoms.

This adds a gut-specific dimension to the CBD immune research reviewed in RTHC-00098 (CBD and innate immunity). While that review covered broad immunomodulatory effects across organ systems, this study drills into the intestinal lining specifically and identifies the molecular mechanism. The miRNA pathway is a more sophisticated finding than simple cytokine suppression and suggests CBD's immune effects may be more targeted than previously understood.

In vitro study — intestinal cells in a dish don't replicate the complexity of a living gut with its microbiome, immune cells, and multiple tissue layers. High-dose growth inhibition raises safety questions that need in vivo testing. The five extracts were high-CBD but not pure CBD — other compounds in the extracts may contribute to effects. Concentrations tested may not reflect what reaches intestinal cells after oral CBD consumption. No disease model — the TNF/IFN stimulation mimics inflammation broadly, not a specific bowel disease.